U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07773129) titled 'A Study to Learn How ASP3082 is Processed in Healthy Men' on Aug. 16.
Brief Summary: Setidegrasib (ASP3082) is being developed for certain cancers. In this study, the researchers want to understand how it is processed by the body in healthy male volunteers.
To do this, [14C] which is a certain chemical (called a tracer, or radionuclide) has been added to setidegrasib. [14C] gives off radiation, but the dose is very low (about the same as the dose from an x-ray) and will leave the body within a few days. [14C] will be picked up by a scanner and will be used to follow setidegrasib through the body. [14C]setidegrasib will be given as ...